Physician profile

Rhett J Eckmann

Family Medicine · West Point, NE

NPI 1205922465

$229.80

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$125.97

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $85.77 2021-2024 Ubrelvy
Astrazeneca Pharmaceuticals Lp $29.02 2022-2024 Airsupra
Merck Sharp & Dohme LLC $26.04 2023 Vaxelis, Gardasil 9, Vaxneuvance
Novo Nordisk INC $16.51 2023 Ozempic, Rybelsus
Lundbeck LLC $15.51 2023 Rexulti
Amgen INC. $15.13 2019
Astellas Pharma US INC $14.36 2024 Veozah
Novartis Pharmaceuticals Corporation $13.83 2019
Allergan, INC. $13.63 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rhett J Eckmann

$229.80

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/9563/rhett-j-eckmann

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.